DarioHealth Corp. (DRIO) Reports Q3 Loss, Lags Revenue Estimates

Core Insights - DarioHealth Corp. reported a quarterly loss of $1.85 per share, which was better than the Zacks Consensus Estimate of a loss of $2.63, representing an earnings surprise of +29.66% [1] - The company posted revenues of $5.01 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 12.47%, and down from $7.42 million a year ago [2] - DarioHealth shares have declined approximately 25.3% year-to-date, contrasting with the S&P 500's gain of 16.5% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$1.54 on revenues of $6.41 million, and for the current fiscal year, it is -$9.83 on revenues of $24.25 million [7] - The estimate revisions trend for DarioHealth was favorable prior to the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Instruments industry, to which DarioHealth belongs, is currently ranked in the top 24% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]